DURHAM, N.C. (PRWEB) January 06, 2020
A new, safe and efficient way to coax stem cells into bone cells is reported in a recently published article from STEM CELLS Translational Medicine (SCTM). The protocol, developed by researchers at the University of Sydney, Australian Research Centre (ARC) for Innovative BioEngineering, could lead to a shift in the treatment of bone regenerative medicine.
Large bone defects and loss due to cancer or trauma can result in scar tissue that impairs the bones ability to repair and regenerate. The current gold standard therapy, autografting, has inherent drawbacks, including limited availability and donor site morbidity. This leaves researchers seeking an alternative source of bone cells and makes bone tissue engineering a growing field with considerable translational potential.
The success of induced pluripotent stem cell (iPSC) technology to reprogram fibroblasts into progenitor cells of various lineages offers an exciting route for tissue repair and regeneration, said Zufu Lu, Ph.D., a member of the University of Sydneys Biomaterials and Tissue Engineering Research Unit and a research associate at the ARC for Innovative BioEngineering. He is a co-lead investigator of the SCTM study, along with Professor Hala Zreiqat, Ph.D., head of the research unit and director of the ARC Training Centre for Innovative BioEngineering.
However, while iPSC technology represents a potentially unlimited source of progenitor cells and allows patients to use their own cells for tissue repair and regeneration thus posing little or no risk of immune rejection the technology has several constraints. Among them are the requirement for complex reprogramming using the Yamanaka factors (Oct3/4, Sox2, Klf4, c-Myc). To add to the complexity, specific stimuli are required to direct iPSCs to re-differentiate to progenitor cells of the lineage of interest.
In addition, Dr. Lu said, any remaining iPSCs pose the risk of tumors following implantation.
One potential way around this, as demonstrated by recent studies, is through the direct reprogramming of fibroblasts into bone cells. Fibroblasts are morphologically similar to osteoblasts. Their similar transcriptomic profiles led us to hypothesize that distinct factors produced by osteoblasts may be capable of coaxing fibroblasts to become osteoblast-like cells, Prof. Zreiqat said.
Previous studies aimed at using fibroblasts to produce various cell types relied on the genetic manipulation of one or more transcription regulators. But just as with iPSCs, reprogramming fibroblasts in this manner has its own inherent technical and safety issues. The Lu-Zreiqat team, however, surmised that an approach employing natural factors might just allow better control over reprogramming and improve the safety.
Unlike genetic reprogramming, chemical induction of cell reprogramming is generally rapid and reversible, and is also more amenable to control through factor dosage and/or combinations with other molecules, Dr. Lu explained.
The team initially determined that media conditioned by human osteoblasts can induce reprogramming of human fibroblasts to functional osteoblasts. Next, said Prof. Zreiqat, our proteomic analysis identified a single naturally bioactive protein, insulin growth factor binding protein-7 (IGFBP7), as being significantly elevated in media conditioned with osteoblasts, compared to those with fibroblasts.
This led them to test IGFBP7s ability as a transcription factor. They found it, indeed, successfully induced a switch from fibroblasts to osteoblasts in vitro. They next tested it in a mouse model and once again experienced success when the fibroblasts produced mineralized tissue. The switch was associated with senescence and dependent on autocrine IL-6 signaling.
The approach we describe in our study has significant advantages over other commonly used cell sources including iPSCs and adult mesenchymal stem cells, Dr. Lu and Prof Zreiqat concluded.
Bone tissue engineering is a growing field where cell therapies have considerable translational potential, but current cell-based approaches face limitations, said Anthony Atala, M.D., Editor-in-Chief of STEM CELLS Translational Medicine and director of the Wake Forest Institute for Regenerative Medicine. The novel observation described in this study could potentially lead to a shift in the current paradigm of bone regenerative medicine.
This study was conducted in collaboration with the Charles Perkins Centre and the Childrens Hospital at Westmead, University of Sydney.
The full article, Reprogramming of human fibroblasts into osteoblasts by insulin-like growth factor binding protein 7, can be accessed at https://stemcellsjournals.onlinelibrary.wiley.com/doi/abs/10.1002/sctm.19-0281.
About STEM CELLS Translational Medicine: STEM CELLS Translational Medicine (SCTM), co-published by AlphaMed Press and Wiley, is a monthly peer-reviewed publication dedicated to significantly advancing the clinical utilization of stem cell molecular and cellular biology. By bridging stem cell research and clinical trials, SCTM will help move applications of these critical investigations closer to accepted best practices. SCTM is the official journal partner of Regenerative Medicine Foundation.
About AlphaMed Press: Established in 1983, AlphaMed Press with offices in Durham, NC, San Francisco, CA, and Belfast, Northern Ireland, publishes two other internationally renowned peer-reviewed journals: STEM CELLS (http://www.StemCells.com), celebrating its 38th year, is the world's first journal devoted to this fast paced field of research. The Oncologist (http://www.TheOncologist.com), also a monthly peer-reviewed publication, entering its 25th year, is devoted to community and hospital-based oncologists and physicians entrusted with cancer patient care. All three journals are premier periodicals with globally recognized editorial boards dedicated to advancing knowledge and education in their focused disciplines.
About Wiley: Wiley, a global company, helps people and organizations develop the skills and knowledge they need to succeed. Our online scientific, technical, medical and scholarly journals, combined with our digital learning, assessment and certification solutions, help universities, learned societies, businesses, governments and individuals increase the academic and professional impact of their work. For more than 200 years, we have delivered consistent performance to our stakeholders. The company's website can be accessed at http://www.wiley.com.
About Regenerative Medicine Foundation (RMF): The non-profit Regenerative Medicine Foundation fosters strategic collaborations to accelerate the development of regenerative medicine to improve health and deliver cures. RMF pursues its mission by producing its flagship World Stem Cell Summit, honouring leaders through the Stem Cell and Regenerative Medicine Action Awards, and promoting educational initiatives.
Originally posted here:
New protocol could signal shift in bone regenerative medicine - PR Web
- Discovery clears hurdle in growing organs for transplants : Newsroom - UT Southwestern - September 26th, 2024
- Cell Therapy Market is Expected to Gain USD 60696.42 Million with a Growing CAGR of 19.20% by 2030 - openPR - September 25th, 2024
- Stem Cell Therapy Market To Reach USD 44 Billion By 2032 (Updated 2024) - Market.us Media - United States Market News - September 25th, 2024
- Doctors cured her sickle-cell disease. So why is she still in pain? - Nature.com - September 23rd, 2024
- The new frontier of luxury travel is a $44,000 course of stem cells and a longevity club stocked with IV stations - Fortune - September 23rd, 2024
- How stem cell and gene therapies are revolutionising healthcare - Express Healthcare - September 20th, 2024
- Exploring Regenerative Medicine and Its Impact on Modern Disease Management - Baltimore Post-Examiner - September 18th, 2024
- Stem Cell Therapy Market Dynamics: Size, Share, and Growth - openPR - September 16th, 2024
- Stem Cell Restore Review: Can It Boost Your Stem Cell Activity for Lasting Health? - Vashon-Maury Island Beachcomber - September 14th, 2024
- Stem Cell Therapy Market valued at USD 3.40 Billion by 2030 As Revealed In New Report - WhaTech - September 14th, 2024
- Stem Cell Manufacturing Market Projected to Witness Huge Growth by 2024-2031 As Revealed In New Report - WhaTech - September 14th, 2024
- Tesla BioHealing and Cell Biotechnology Partner to Advance Stem Cell Therapies - Vancity Buzz - September 12th, 2024
- Meso Numismatics Announces Cellgenics Sponsorship of Three Prominent Regenerative Medicine Events in Peru This September - StockTitan - September 10th, 2024
- Meso Numismatics Announces Cellgenics Sponsorship of Three Prominent Regenerative Medicine Events in Peru This September - Newswire - September 10th, 2024
- Breakthrough in blood stem cell development offers hope for leukemia and bone marrow failure - News-Medical.Net - September 8th, 2024
- Stem Cell Therapy Market Is Estimated To Reach $928.6 Million by 2031 | CAGR 16.2% - EIN News - September 8th, 2024
- USC researchers receive funding to develop next generation of intelligent biocomputers - EurekAlert - September 8th, 2024
- Risk Factors and Indications for Stem Cell Transplants in MDS - Targeted Oncology - September 6th, 2024
- Cell Therapy Market Size to Hit USD 28.98 Billion by 2032, - GlobeNewswire - September 6th, 2024
- Blood stem cells grown in the lab for the first time ever - Earth.com - September 6th, 2024
- Top 3 Grants in Regenerative Medicine: August 2024 - RegMedNet - September 6th, 2024
- New approach moves cell therapy closer to treating many disorders - Medical Xpress - September 4th, 2024
- Stem Cell Therapy Mexico: R3 Stem Cell Unveils Innovative and Affordable Non-Invasive Solutions - openPR - September 4th, 2024
- What Sets Immunotherapy Regenerative Medicine Apart in a Crowded Regenerative Market? - Flaunt Magazine - September 2nd, 2024
- Tiny Test Tubes Sort Stem Cells for Improved Therapy - The Scientist - August 31st, 2024
- Dr. Crandall: Stem Cell Treatment Heals the Heart - Newsmax - August 31st, 2024
- From stem cells to technology, the next Wisconsin RISE initiative focuses on improving health - University of Wisconsin-Madison - August 29th, 2024
- aHSCT Stem Cell Therapy for MS | National MS Society - National MS Society - August 29th, 2024
- Are Stem Cells the Secret to Anti-Aging? - The Edge - August 22nd, 2024
- A Comprehensive Review of the Role of Stem Cells in Neuroregeneration: Potential Therapies for Neurological Disorders - Cureus - August 22nd, 2024
- Scientists discover method to activate dormant stem cells in the brain - Medical Xpress - August 20th, 2024
- New way to extend 'shelf life' of blood stem cells can improve gene therapy - Medical Xpress - August 20th, 2024
- Where Are the Cell Therapies for Type 1 Diabetes? - Inside Precision Medicine - August 14th, 2024
- BioRestorative Therapies Reports Second Quarter 2024 Financial Results and Provides Business Update - GlobeNewswire - August 14th, 2024
- Stem Cell Therapy Market to expand to a market value of USD 3.40 Billion by 2030, with a CAGR of 13.4 percentage - openPR - August 14th, 2024
- Stem cell therapy unveiled: Discover the truth and boost donor rates - IOL - August 12th, 2024
- Stem Cell Therapy Market Set to Skyrocket to $48.89 Billion by 2033, Fueled by 13.2% CAGR - BioSpace - August 10th, 2024
- T.J. Watt Reveals He Received Stem Cell Treatment On Knee This Offseason - Steelers Depot - August 10th, 2024
- Anti-aging enthusiasts are getting $16,500 injections to make their knees young again - Business Insider Nederland - August 10th, 2024
- Regenerative Medicine Market Exclusive Insights on Size, Share and Profit - WhaTech - August 8th, 2024
- Fresh Study Reveals the Mesenchymal Stem Cells Market Trends, Strategy and Overview - WhaTech - August 6th, 2024
- Allogeneic Stem Cell Transplantation Market Exclusive Survey Report with Detailed Analysis to 2031 By Top R... - WhaTech - August 6th, 2024
- Salk awarded $3.6 million by the California Institute for Regenerative Medicine to advance research on brain aging - Salk Institute - August 2nd, 2024
- Professor awarded grant to study stem cell therapy for inflammatory bowel disorders - Mercer University - August 2nd, 2024
- Stem cell therapy advances: MSCs show potential in managing COVID-19 and influenza infections - News-Medical.Net - July 31st, 2024
- Scientists aboard international space station perform stem cell research and biomanufacturing in microgravity - BioProcess Insider - July 31st, 2024
- UCLA receives $2 million to develop regenerative medicine therapies for spinal cord injury - UCLA Newsroom - July 31st, 2024
- The Phoenix of stem cells: pluripotent cells in adult tissues and peripheral blood - Frontiers - July 31st, 2024
- Regenerative Medicine Market to Reach USD 194.9 Billion by 2032 - Market.us Media - United States Market News - July 31st, 2024
- Stem Cell Exosome Therapeutic Market Business Insights, Key Trend Analysis - Economica - July 31st, 2024
- One of the 7 people cured of HIV tells his story. Can his cure work for others? - Michigan Public - July 31st, 2024
- Novel stem cell treatment for osteoarthritis reduces pain by 58% - NewsBytes - July 30th, 2024
- Stem Cell Manufacturing Market Size To Reach $21.8 Billion By 2028 As Revealed In New Report - WhaTech - July 30th, 2024
- PRP, stem cell therapyhelp in curing infertility - The Times of India - July 30th, 2024
- Australian researchers develop a donor stem cell therapy for the successful treatment of osteoarthritis - News Hub - July 28th, 2024
- Seventh patient cured of HIV: why scientists are excited - Nature.com - July 28th, 2024
- Enggartiasto Lauds Stem Cell Therapy at RSCM - Jakartaglobe.id - July 28th, 2024
- Investigating the effect of alemtuzumab in allogeneic hematopoietic cell transplantation - Medical Xpress - July 28th, 2024
- Does This 'Stem Cell' Therapy Contain Any Actual Stem Cells? - Medscape - July 22nd, 2024
- Stem Cells and Malignant Mesothelioma - Mesothelioma.net Blog - July 18th, 2024
- Selma Blair on Getting Back on Track With MS Treatment: People Dont Get How Expensive It Is to Be Disabled - Hollywood Reporter - July 18th, 2024
- Common therapies contain different cell types, study finds - News-Medical.Net - July 18th, 2024
- Stem Cell Therapy with Saffron Extract Promotes Uterine Healing - Natural Science News - July 18th, 2024
- Half-matched stem cell transplant on 11-yr-old boy - The Times of India - July 12th, 2024
- Efficacy and Safety of Stem Cell Therapy for Orthopedic Conditions, Including Osteoarthritis and Bone Defects - Cureus - July 8th, 2024
- Stem Cell Therapy Market Poised to Reach USD 52.1 Billion by 2034 at a 12.1% of CAGR - PharmiWeb.com - July 8th, 2024
- "Living Fillings" Could be the Future Thanks to Stem Cells - NewBeauty Magazine - July 8th, 2024
- R3 Stem Cell Wins 2024 Global Regenerative Medicine Company of the Year for Third Time - EIN News - July 8th, 2024
- NUS Medicine team aims to start clinical trial of targeted therapy for deadly brain cancer in 2025 - The Straits Times - July 8th, 2024
- Sorting therapeutic stem cells by function improves healing after heart attack, lab study shows - Medical Xpress - July 4th, 2024
- July: cruk-grant | News and features - University of Bristol - July 4th, 2024
- Stem cell therapy shows promise for hirschsprung disease - Open Access Government - June 30th, 2024
- Stem Cells & Other Injectable Treatments: Solution or Scam? Episode 3 of 'The Bone Whisperers' Podcast - NYU Langone Health - June 28th, 2024
- Modulation of adipose-derived stem cell behavior by prostate pathology-associated plasma: insights from in vitro ... - Nature.com - June 28th, 2024
- Advancing regenerative medicine therapies UCI News - UCI News - June 26th, 2024
- Stem cell therapy could be breakthrough against type 1 diabetes - Medical Xpress - June 26th, 2024
- Paving the Way Toward Transplantation: NIH Awards Support Ophthalmology Retinal Research - University of Colorado Anschutz Medical Campus - June 26th, 2024
- Stem Cell Therapy Could Be Breakthrough Against Type 1 Diabetes - The Caledonian-Record - June 26th, 2024
- Some hawking stem cells say they can treat almost anything. They can't - Niagara Gazette - June 24th, 2024
- The evolution of cell therapy to address unmet medical needs - Drug Target Review - June 19th, 2024
Recent Comments